newsfilter
← Latest News
GlobeNewswire·

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growt